Emergent BioSolutions Acquires Evolva's Anti-bacterial Programme - Quick Facts

(RTTNews) - Evolva Holding SA (ELVAF.PK) announced that Emergent BioSolutions Inc. (EBS) has acquired Evolva's anti-bacterial programme, the EV-035 series. For Evolva, the deal is worth up to $70.5 million plus royalties.

The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. Evolva and Emergent are working closely with Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense on the transfer of the funding contract to Emergent, and expect the process to be completed within the next few weeks.

"Emergent's acquisition of the EV-035 series of broad spectrum antibiotics further aligns the company with the U.S. government's strategic objective of combating antibiotic-resistant bacteria, which the Administration considers a national security priority that requires continued development funding," said Adam Havey, Executive Vice President and President, Biodefense Division of Emergent BioSolutions.